[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stevens-johnson-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stevens-johnson-syndrome":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,82,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100587291","phase-1-subconjunctival-humira-for-boston-keratoprosthesis-100587291",false,"NCT06926478","Subconjunctival Humira for Boston Keratoprosthesis","Clinical Trial to Evaluate Short-term Safety of Subconjunctival Adalimumab in Combination With Type 1 Boston Keratoprosthesis Implantation","Inclusion Criteria:\n\n* Age 18 years or older\n* Individuals eligible for keratoprosthesis surgery, as determined by standard-of-care eligibility criteria\n* Patients with poor prognosis for corneal transplantation, severe corneal opacity and\u002For vascularization\n* Patients with vision worse than 20\u002F200 in the eligible eye, and contralateral eye with vision less than 20\u002F40\n* Patients with intact nasal light projection\n* Willing and able to comply with study plan for the full duration of the study\n* Willing and able to sign a written informed consent\n\nExclusion Criteria:\n\n* Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-# release assay \\[IGRA\\] test, such as Quantiferon-gold)\n* Untreated active hepatitis B or C infection.\n* Ocular or periocular malignancy and\u002For infection\n* Inability to wear contact lens\n* Pregnancy (positive pregnancy test) or lactating\n* Participation in another interventional study at the time of screening\n* Any of the following baseline lab values\n\n  1. White blood count \\\u003C3500 cells per microliter\n  2. Platelets \\\u003C100,000 per microliter\n  3. Hematocrit \\\u003C30%\n  4. AST or ALT \\>1.5X upper limit normal value\n* Multiple sclerosis or other demyelinating disease\n* Severe uncontrolled infection\n* Moderate to severe heart failure (NYHA class III\u002FIV)\n* Active malignancy\n* History of adalimumab intolerance\n* Pregnancy or lactation\n* Medical problems or drug or alcohol dependence problems sufficient to prevent adherence to treatment and study procedures.\n* As judged by the investigator any patients that are questionable for their suitability in the study","ALL","18 Years",{"count":19,"type":20},8,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.",[26,27,28,29],"Penetrating Keratoplasty","Multiple Graft Failure","Ocular Cicatricial Pemphigoid","Stevens-Johnson Syndrome",[31,32,33,34],"Kpro","Boston Kpro","Keratoprosthesis","Type-1 Boston Kpro","NOT_YET_RECRUITING","2026-03-23",{"date":38,"type":39},"2026-03-27","ACTUAL",{"date":41,"type":20},"2026-06-01",{"date":43,"type":20},"2028-06-01",{"name":45,"class":46},"Massachusetts Eye and Ear Infirmary","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100594024","phase-2-autologous-serum-obtained-by-a-closed-circuit-collection-device-100594024","NCT07014059","Autologous Serum Obtained by a Closed-Circuit Collection Device","\"In Vivo Evaluation of Topical Ocular Use of Autologous Serum Obtained by a Closed-Circuit Collection Device.\"","Inclusion Criteria:\n\n* ≥ 18 years\n* Dry eye and\u002For chronic epithelial defects of the ocular surface with indication for autologous serum according to the evaluation of ophthalmologists specialized in Cornea and Ocular Surface;\n* Peripheral venous access or PICC that allows the collection of whole blood.\n\nExclusion Criteria:\n\n* Active ocular infection;\n* Hemoglobin \\\u003C 11 g\u002FdL;\n* Angina, MI, or stroke in the last 30 days;\n* Significant pulmonary or cardiac disease that contraindicates autologous serum collection in the investigator's opinion;\n* Active ocular or systemic infection at the time of collection;\n* Inability to attend follow-up visits at 6 and 12 weeks;\n* Active hematological malignancy (except measurable residual disease) or solid malignancy (except non-melanoma skin cancer);\n* Positive for HIV, HCV, HBV, HTLV, Chagas disease, or syphilis;\n* Life expectancy \\\u003C 6 months;\n* Not pregnant (as reported by the participant).",{"count":56,"type":20},16,[58],"PHASE2","Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions. This pilot trial assesses the feasibility of collecting ASED in a closed-circuit system for patients with chronic ocular surface diseases.",[61,62,29,63,64,65,66],"GVHD","Meibomian Gland Dysfunction (Disorder)","Limbal Keratoconjunctivitis","Recurrent Erosions of Persistent Epithelial Defects","Neurotrophic Ulcer","Sjogren Syndrome With Keratoconjunctivitis",[68,69,70,62,29,63,65,64,71,72],"soro autologo","gvhd","Sjogren's Syndrome (SS)","Study Protocol - Autologous Serum","Autologous Serum","2025-06-02",{"date":75,"type":39},"2025-06-10",{"date":77,"type":20},"2025-06-20",{"date":79,"type":20},"2027-06-20",{"name":81,"class":46},"GIANCARLO FATOBENE",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":101,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":47},"100336346","drug-reactions-sampling-collectiontoxidermies-100336346","NCT03659227","Drug Reactions Sampling (COLLECTIONTOXIDERMIES)","Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples","Inclusion Criteria:\n\n* Patient ≥ 18 y-old\n* Severe cutaneous drug reaction (AGEP, DRESS, SJS\u002FTEN, generalized bullous fixed drug eruption), drug-induced IgA bullous dermatosis, maculopapular exanthema, erythema multiforme\n* Signed consent\n* Social security affiliation\n\nExclusion Criteria:\n\n* Patients law protection",{"count":90,"type":20},500,"OBSERVATIONAL","Intro: Dermatology department of Henri Mondor Hospital (Creteil, France), is a reference center for toxic bullous diseases and severe cutaneous drug reactions (Stevens-Johnson syndrome (SJS), Lyell syndrome (toxic epidermal necrolysis (TEN)), generalized bullous fixed drug reactions, AGEP, DRESS, drug induced immunoglobulin A (IgA) bullous dermatosis, and erythema multiforme). In order to conduct clinical and biological research studies in drug reactions, it is necessary for the investigator's department to implement a collection of clinical data and biological samples.\n\nHypothesis\u002FObjective: To collect clinical data and cutaneous and biological samples for immunological, biological and genetic studies to improve knowledge about pathophysiology of drug reactions.\n\nMethod: The following samples will be performed in addition to the routine practice samples: one skin punch biopsy (6mm); 43 mL of blood; blister fluid aspiration; oral and nose mucous membrane and skin eSWABs, stool samples.\n\nThese samples will be stored in a dedicated biological sampling department (\"Platform of biological resources\").\n\nConclusion: The implementation of this collection should allow us to conduct pathophysiological studies about drug reactions.",[29,94,95,96,97,98,99,100],"Lyell Syndrome","Drug Reactions","AGEP","DRESS","Bullous Dermatosis Caused by Drug Treatment (Disorder)","Maculopapular Exanthem","Erythema Multiforme",[102,103,104,94,105,96,97,106,107,108,109,110],"Drug reactions","severe cutaneous adverse reactions (SCARs","Stevens-Johnson syndrome","(generalized bullous) fixed drug reaction","drug induced IgA bullous dermatosis","maculopapular exanthema","erythema multiforme","sampling","collection","RECRUITING","2022-05-02",{"date":114,"type":39},"2022-05-03",{"date":116,"type":39},"2018-09-26",{"date":118,"type":20},"2028-09-25",{"name":120,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":135,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100220642","clinical-trial-on-the-effect-of-autologous-oral-mucosal-epithelial-sheet-transplantation-100220642","NCT02149732","Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation","An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients","Inclusion Criteria:\n\n1. patient with eye which has limbal stem cell deficiency and conjunctivalization of cornea\n2. patient who shows no improvement after limbal tissue or amniotic membrane transplantation, or who has difficulty in receiving long-term immunosuppressive treatment\n3. patient who agree this clinical trial\n4. patient with the eyes in which best corrected visual acuity is less than counting finger\n5. patient who is older than sixteen year old\n\nExclusion Criteria:\n\n1. patient who has relevant corneal transparency\n2. patient who is on the pregnancy or has a plan of pregnancy within 1 year\n3. patient who has corneal infection\n4. patient who has diagnosis of HBV, HCV, HIV, syphilis\n5. patinet who has past medial history of antinal, myocardial infarction, heart failure, arrhythmia, brain stroke, cerebrovascular disease\n6. patient who has malignancy\n7. patient who shows hypersensitivity to bovine protein.","16 Years","EXPANDED_ACCESS","To investigate the effect of ocular surface reconstruction and assess the safety in cultivated oral mucosal epithelial cell sheet transplantation (COMET) regarding patients with cicatricial change of ocular surface.",[132,133,28,134],"Limbal Stem Cell Deficiency","Stevens-johnson Syndrome","Chemical Burn",[136,137,138],"Limbal stem cell deficiency","Cultivated oral mucosal cell sheet transplantation","Ocular surface reconstruction","AVAILABLE","2016-04-18",{"date":142,"type":20},"2016-04-20",{"date":144,"type":4},"2014-05",{"date":146,"type":20},"2016-12",{"name":148,"class":46},"Seoul National University Hospital",2,"Stevens Johnson Syndrome"]